Last reviewed · How we verify

Disorder of lung — Treatment Landscape & Competitive Intelligence

Disorder of lung (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disorder of lung, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Theophyllin Theophyllin University of Bergen Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1
Aminophyllin Aminophyllin University of Padova Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. University of Bergen · 1 drug in Disorder of lung
  2. University of Padova · 1 drug in Disorder of lung

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disorder of lung:

Cite this brief

Drug Landscape (2026). Disorder of lung — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disorder-of-lung. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing